ADAM

About Contraline

Contraline is pioneering the first major innovations in male contraception since the vasectomy, addressing a significant and long-standing gap in reproductive health. The company's pipeline features two distinct product candidates: NES/T, a daily topical gel, and ADAM, a long-acting implant, both aimed at providing reversible sperm suppression. With its lead gel having reportedly completed clinical trials in 2025, Contraline is positioned as a frontrunner in a nascent but high-potential market. The company is backed by experienced leadership, a strong scientific advisory board, and venture capital, aiming to bring much-needed choice and equity to contraceptive responsibility.

Therapeutic Areas

Other Male Contraception Drugs